Hl 60 atcc ccl240

Manufactured by American Type Culture Collection

Sourced in United States

HL-60 (ATCC® CCL240™) is a human myeloid leukemia cell line that can be used for various research applications. It is a suspension cell line derived from the peripheral blood of a patient with acute promyelocytic leukemia.

Automatically generated - may contain errors

Lab products found in correlation

Ficoll paque plus, by GE Healthcare (2 mentions) Thp 1 atcc tib 202, by American Type Culture Collection (2 mentions) K562 atcc ccl 243, by American Type Culture Collection (1 mentions) Rpmi 1640 media, by Thermo Fisher Scientific (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Penicillin streptomycin, by GE Healthcare (1 mentions) Fetal bovine serum (fbs), by GE Healthcare (1 mentions) Amphotericin b, by GE Healthcare (1 mentions) Rpmi 1640 medium, by Merck Group (1 mentions) Trypan blue, by Merck Group (1 mentions) Histopaque 1077, by Merck Group (1 mentions) Rpmi 8226 atcc ccl 155, by American Type Culture Collection (1 mentions)

Close spelling variants of this product

HL-60 (480 citations) ATCC® CCL240™) (7 citations)

5 protocols using hl 60 atcc ccl240

Cell Line and Primary Cell Culture

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human promyelocytic leukemia cells (HL60 ATCC CCL-240) and chronic myelogenous leukemia (K562 ATCC CCL-243) were purchased from ATCC and authenticated by STR repeats (Biosynthesis, Lewisville TX). Cell lines were grown in a maintenance medium culture: RPMI medium, supplemented with fetal bovine serum (20% in HL60, HMC and 10% in K562 cells), 1% penicillin-streptomycin, these were incubated at 37 °C in a humidified 5% CO₂ atmosphere. The Human Mononuclear Cells (HMC) were obtained from hematologically normal patients undergoing orthopedic surgery. The procedures were performed at the Hematology Department, Medical Specialties Hospital, La Raza Medical Center IMSS, Mexico City, and the Hip Surgery Department, Villa Coapa Hospital, IMSS, Mexico City, respectively. The HMC were isolated using Ficoll Paque Plus (Pharmacia Biotech, Uppsala, Sweden). Cells were then resuspended in RPMI advanced medium and total numbers of nucleated and viable cells were determined with a hemocytometer, using Turck solution and trypan blue stain, respectively. HMC were collected according to institutional guidelines, including written informed consent from each donor.
All procedures were approved by the Ethics and Scientific Committee at IMSS with number R-2013-3602-6 (15 (link)).

Quintal-Novelo C., Valencia-Chan L., Chávez-González A., Rangel-Méndez J, & Moo-Puc R. (2022). A Morinda royoc Root Extract and Fractions Exhibit Antigiardial Activity without Affecting Cell Viability. Iranian Journal of Parasitology, 17(2), 259-267.

+ Open protocol

+ Expand

Isolation of Primary AML and Normal Bone Marrow Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary AML cells were isolated from freshly collected bone marrow using Ficoll-Paque^TM PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to the manufacturer’s instructions if the leukemia cells accounted for more than 90% of non-erythroid mononucleated cells of bone marrow. Normal bone marrow nucleated cells were harvested using Ficoll-Paque^TM PLUS from patients with treatment-naive non-Hodgkin’s lymphoma for whom bone marrow examination for lymphoma staging was performed but determined to be normal. All bone marrow samples were obtained under a protocol approved by the China Medical University Hospital internal review board (CMUH102-REC1-124 issued on 26 May 2014). Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Human AML cell lines HL-60 (ATCC CCL-240) and THP-1 (ATCC TIB-202) were from American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were incubated in RPMI-1640 media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and penicillin (100 U/mL)/streptomycin (100 µg/mL) (Invitrogen) at 37 °C in the presence of 5% CO₂.

Chiu C.F., Weng J.R., Jadhav A., Wu C.Y., Sargeant A.M, & Bai L.Y. (2016). T315 Decreases Acute Myeloid Leukemia Cell Viability through a Combination of Apoptosis Induction and Autophagic Cell Death. International Journal of Molecular Sciences, 17(8), 1337.

+ Open protocol

+ Expand

Culturing HL-60 Leukemia Cell Line

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human promyelocytic leukemia cell line HL-60 (ATCC® CCL240™) was purchased from the American Type Culture Collection (ATCC, USA). HL-60 cells were commonly cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum containing 100 U/ml penicillin and 100 U/ml streptomycin at 37 °C in a humidified atmosphere with 5% CO₂. All experiments were performed only when the cells were growing during the exponential phase.

Fan Y., Chiu J.F., Liu J., Deng Y., Xu C., Zhang J, & Li G. (2018). Resveratrol induces autophagy-dependent apoptosis in HL-60 cells. BMC Cancer, 18, 581.

+ Open protocol

+ Expand

Leukemia Cell Line Maintenance and Inhibitor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols

HL-60 (ATCC CCL-240), K562
(ATCC CCL-243), CCRF-CEM (ATCC CRM-CCL-119), and RL (ATCC CRL-2261) leukemia cell lines were obtained from the American Type
Culture Collection (ATCC), Middlesex. HL-60 and K562 cell lines are
deoxynucleotidyl transferase-negative (TdT^–ve),
whereas CCRF-CEM cell line is TdT^+ve. They were cultured
in RPMI-1640 medium (Sigma-Aldrich, U.K.), which were supplemented
with 10% fetal bovine serum (FBS) (PAA Laboratories), 1% amphotericin
B (5.5 mL), and 1% penicillin/streptomycin (5.5 mL) (PAA Laboratories)
and grown in flasks at 37 °C in an incubator with 5% CO₂. For the studies with inhibitors, the cells were treated with 10
μM nitrobenzylthioinosine (NBTI, hENT inhibitor) or 1 μM
EHNA (EHNA hydrochloride) or A-134974 (A-134974 dihydrochloride hydrate)
and left for 5 min before adding the drug. The cells were then incubated
for 2 h at 37 °C with 5% CO₂.

Serpi M., Ferrari V., McGuigan C., Ghazaly E, & Pepper C. (2022). Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3′-Deoxyadenosine, as a Potential Anticancer Agent. Journal of Medicinal Chemistry, 65(23), 15789-15804.

+ Open protocol

+ Expand

Cultivation and Characterization of Leukemia Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPMI8226 (ATCC^® CCL-155^™) myeloma cancer cells, HL60 (ATCC^® CCL-240^™) promyelocytic leukemia cells and THP1 (ATCC^® TIB-202^™) acute monocytic leukemia cells were purchased from American Type Culture Collection (ATCC, Rockville, USA). Peripheral Blood Mononuclear Cells (PBMC) were isolated from buffy coat obtained from the Central Blood Bank (Lodz, Poland). PBMCs were isolated with Histopaque 1077 (Sigma Aldrich) at density gradient by centrifugation at 300 × g for 15 min.
All investigated cells were grown as a monolayer with RPMI 1640 medium, 1% phytohemaglutinin (only in PBMCs growth medium) supplemented with 10% fetal bovine serum, penicillin (10 U/ml) and streptomycin (50 μg/ml), in standard conditions: 37 °C, 100% humidity, the atmosphere being 5% CO₂ and 95% air. The cell viability was systematically controlled using trypan blue (0.4%, Sigma). In all experiments, cells in logarithmic phase of growth were used when their viability was above 95%.

Gajek A., Poczta A., Łukawska M., Cecuda- Adamczewska V., Tobiasz J, & Marczak A. (2020). Chemical modification of melphalan as a key to improving treatment of haematological malignancies. Scientific Reports, 10, 4479.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!